Protocol Ledger

NCT06010342 · Phase II · RECRUITING

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Interventional Phase II clinical trial protocol NCT06010342 sponsored by Teligene US in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-16 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06010342
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06010342
Protocol FieldVerified Registry Value
NCT IdentifierNCT06010342
Consolidated Lead SponsorTeligene US
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2023-03-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06010342
Hospital Research SiteLocationSite Profile
Texas Oncology (Dallas)Dallas, TXOpen Hospital Dossier ->
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chongqing University Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI